skin cancer

February 18, 2022

Relatlimab and nivolumab in untreated and metastatic melanom

In preclinical models, simultaneous inhibition of LAG-3 and PD-1 showed synergistic antitumor activity. This phase 2-3 study evaluated the combination of relatlimab (anti LAG-3) and nivolumab […]
March 30, 2021

Study suggests that patients with stage IIB/IIC melanoma undergoing surgical resection showed survival gain with immunotherapy

The risk of locoregional and distance recurrence of cutaneous melanoma in stage IIB/IIC is high and there is limited evidence on the clinical benefit of adjuvant […]
August 27, 2020

Damage to spermatogenesis may be associated with immunotherapy, study suggests

Establishing the association of immunotherapy with spermatogenesis is an essential step for the preservation of male fertility A research letter published in JAMA Oncology recently discussed […]
July 22, 2020

Real-world analysis of nivolumab dosing regimens show that duration of therapy and adverse effects are similar for doses every 2 or 4 weeks

The analysis was performed in an oncology setting of the American community Real-world results of adjuvant treatment of melanoma in an American community oncology setting were […]
July 22, 2020

Update of OpACIN and OpACIN-neo trials indicates benefit of neoadjuvant immunotherapy in patients with stage IIIB / IIIC melanoma

Update data on recurrence-free survival were evaluated in the OpACIN and OpACIN-neo trials, which were presented at AACR 2020 Update data on 36- and 18-month recurrence-free […]
May 7, 2020

Results from the IMspire150 and SWOG S1320 studies are released during the AACR Virtual Meeting 2020

Experts released two important studies on the use of targeted therapy and immunotherapy in the metastatic melanoma scenario During the virtual presentation of the AACR (American […]